A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
The best Bull and Bear pitches based on recency and number of recommendations.
Sales should improve dramatically--medicare approved, centers set,reached their goal on centers and everything should follow--earnings growth will follow
The large debt situation at Dendreon coupled with an inadequate amount of revenue will lead to the company having a hard time attracting investors.
Read the most recent pitches from players about DNDNQ.
Recs
it will lose more and more revenu to big pharma
Recs
The large debt situation at Dendreon coupled with an inadequate amount of revenue will lead to the company having a hard time attracting investors.
Recs
This stock is undervalued and has great potential
Find the members with the highest scoring picks in DNDNQ.
jack0071 (63.23) Score: +1,228.96
The Score Leader is the player with the highest score across all their picks in DNDNQ.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
BioMedReports | < 20 | 3/30/2009 | 3W | $4.39 | -99.26% | +549.93% | +649.19 | 0 Comment | ||
RockyJS1 | 86.86 | 4/8/2009 | 3M | $6.68 | -99.51% | +526.45% | +625.96 | 0 Comment | ||
tonylogan1 | 27.70 | 4/20/2009 | 3M | $19.82 | -99.84% | +519.19% | +619.03 | 1 Comment | ||
markhs | < 20 | 1/16/2009 | 3Y | $4.36 | -99.25% | +518.12% | +617.38 | 1 Comment | ||
TraderStiz | 29.92 | 4/14/2009 | 5Y | $16.92 | -99.81% | +514.35% | +614.16 | 0 Comment | ||
JustinTheFool | 60.20 | 4/23/2009 | 5Y | $20.37 | -99.84% | +511.81% | +611.65 | 0 Comment | ||
JGus | 27.71 | 4/13/2009 | NS | $7.15 | -99.55% | +510.12% | +609.66 | 14 Comments | ||
examinebeyond | 41.89 | 4/9/2009 | 3W | $6.50 | -99.50% | +508.97% | +608.47 | 0 Comment | ||
anticitradeshort | 30.04 | 4/20/2009 | NS | $18.66 | -99.83% | +505.80% | +605.63 | 0 Comment | ||
watchmesoar | 35.58 | 4/27/2009 | 5Y | $20.33 | -99.84% | +504.35% | +604.19 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.